biostudies-literatureUnknown1(3)Duhrsen UThe PETAL (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas) trial investigated whether treatment intensification after 2 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; plus rituximab [R] for CD20⁺ lymphomas) improved survival in aggressive non-Hodgkin lymphoma. A total of 754 patients (87.5%) had a negative and 108 (12.5%) had a positive interim positron emission tomography (iPET) scan. iPET-positive patients were randomly assigned to receive another 6 (R-)CHOP cycles or 6 blocks of a more intensive protocol. Interim PET-negative patients received another 4 cycles of R-CHOP with or without 2 additional doses of R. After a median follow-up of 4 years, treatment intensification had not improved outcome. These results werBlood neoplasia100018https://www.ebi.ac.uk/biostudies/studies/S-EPMC12082160biostudies-literatureResponse-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.PMC12082160Kneba MRomer WStark UMesters RMahlmann SMoorahrend EPetrasch SKloke OWilop SSelbach JKeller UBehringer DHahn DSpohn CBrenner WGerming UKarsten IEFett WHoffkes HGLimmroth CBeck CTrenn GSchwalenberg MMartens UMNeuhauser MHohler TNiederwieser DStrumberg DMuller-Tidow CDuhrsen USchafer WPlatzbecker UKlapper WPopperl Gvon Verschuer ULink HKlein MFreesmeyer Mde Wit MHochhaus ALa Rosee PKlein AScherag ASchroers RKotzerke JGrube MPETAL Trial InvestigatorsSchutte JGrieshammer MWitzens-Harig MKreisel-Bustgens CReimer PDienst APrange-Krex GNonnemacher MMarienhagen JBaldus CRekowski JGrigoleit GUSchmalz OPlotkin MSteiniger HHeld GHeld HGaska TWeissinger FSchwarzer AMaschmeyer GWorns MAFranzius CHautzel HHolzinger JHerr WTometten MHaberkorn UMoeller RHeil GNyuyki FBuckner URaghavachar AHeuser MRunde VBrink IJockel KHBalleisen JSNuckel HKrohn THertenstein BGiagounidis AJordan KSudhoff TBernhard HWeckesser MSandmann MBockisch AHeike MKorfel AHertel ALutzen UNaumann RLarisch RBengel FMFricke EChemnitz JMSchulte KKroschinsky FHuttmann AKofahl-Krause DStephany MKluge RDurk HfalseResponse-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.The PETAL (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas) trial investigated whether treatment intensification after 2 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; plus rituximab [R] for CD20⁺ lymphomas) improved survival in aggressive non-Hodgkin lymphoma. A total of 754 patients (87.5%) had a negative and 108 (12.5%) had a positive interim positron emission tomography (iPET) scan. iPET-positive patients were randomly assigned to receive another 6 (R-)CHOP cycles or 6 blocks of a more intensive protocol. Interim PET-negative patients received another 4 cycles of R-CHOP with or without 2 additional doses of R. After a median follow-up of 4 years, treatment intensification had not improved outcome. These results wer2024-01-01T00:00:00Z2024 Sep2026-06-01T11:40:05.968Z2026-04-08T11:57:31.607ZS-EPMC120821604045305610.1016/j.bneo.2024.100018